ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

A More Convenient Way to Get Screened for Colon Cancer

(BPT) - Guardant Health

Did you know colorectal cancer (CRC) is one of the most treatable forms of cancer when it's caught in its early stages, yet one in three American adults are not up to date with recommended screening? This means more than 50 million Americans age 45 and older may miss the chance to catch CRC early, when survival rates are as high as 91%. Instead, they may not know they have CRC until it's in late stages, when the chance of survival can plummet to 16%.

Studies show that people at average risk for colon cancer often avoid screening because they think traditional screening options, such as colonoscopies and stool-based tests, are unpleasant or inconvenient. But alternative options, like a simple blood test, may help more people get screened.

Like many Americans, Elissa Brown, a 61-year-old college counseling advisor, was facing this problem. After a loved one was diagnosed with colon cancer, Brown learned firsthand how critical it is to stay up to date with screenings but still had concerns about traditional options being inconvenient or unpleasant.

"I knew how important it is to get checked for colon cancer, but seeing the impact of the disease reinforced how critical screening truly is for everyone," said Brown. "That's why I prioritized talking to my doctor about screening and learning about the different options available."

At her next OB-GYN appointment, Brown asked about CRC screening. While she had used a stool-based test previously, this visit taught her about an alternate approach - Shield, a new blood test that offered a more pleasant screening option for people age 45 and older and at average risk for colon cancer. The test only required a simple blood draw during a routine doctor visit.

Brown decided Shield was the best option for her. She was also confident that she was using a screening method recommended by her OB-GYN's practice and backed by study results published in the New England Journal of Medicine.

After a quick blood draw, Brown received her results about two weeks later, giving her the peace of mind of knowing she not only had a negative result but was also up to date with her screening for colon cancer.

"I was nervous about getting screened for colon cancer, but Shield helped eliminate those fears," she said. "The best part is the test didn't require any preparation or downtime - just a quick blood draw - which is important to me because my life is very busy."

The Shield test is covered by Medicare, so those with Medicare Part B will have no out-of-pocket cost; if you have a Medicare Advantage plan, you may have a copay. Once Shield is included in clinical screening guidelines, many commercial insurance providers are expected to cover it as well.

"I'm so glad I didn't let the stress of a colonoscopy or the 'ick' factor of stool tests stop me from taking care of my health," said Brown. "Early detection can save your life and now the Shield blood test makes screening so easy. It just makes sense to get it done and know your status."

Adults 45 and older who are due for colon cancer screening can talk to their doctor about whether Shield is the right option for them. To learn more about Shield, visit ShieldCancerScreen.com.

Shield is indicated for colorectal cancer screening in individuals at average risk for the disease, age 45 years or older. Patients with a positive result should be followed by colonoscopy. Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals. This test is performed at Guardant Health, Inc.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.